Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMLA Topical Cream for Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy
NCT06223659Phase 2Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Dec 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial in procedural pain comparing Cohort 1 (EMLA cream) with Cohort 2 (placebo cream) (2 cohorts). Primary endpoint: Pain score at 1 year. Started Dec 2023; status: recruiting.
02
Drugs
lidocaine + prilocaine
03
Conditions
procedural pain
Beyond the preview
Go deeper on NCT06223659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223659.